Author

N. Vlahov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 5 Approach:experimental assay· 5 Organism:mouse· 4 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

O. J. Sansom· 4 shared A. D. Campbell· 3 shared C. Nixon· 3 shared K. Gilroy· 3 shared R. A. Ridgway· 3 shared C. A. Ford· 2 shared D. M. Gay· 2 shared S. T. Barry· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

O. J. Sansom

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

C. A. Ford, D. Koludrovic, P. P. Centeno, M. Foth, E. Tsonou, N. Vlahov, N. Sphyris, K. Gilroy, C. Bull, C. Nixon, B. Serrels, A. F. Munro, J. C. Dawson, N. O. Carragher, V. Pavet, , A. D. Campbell

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

bioRxiv · Feb 26, 2024Cancer Biology

eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancers

J. A. Waldron, G. Kanellos, R. C. L. Smith, J. R. P. Knight, J. Munro, C. Alexandrou, N. Vlahov, L. Pardo-Fernandez, M. Moore, S. L. Gillen, D. Strathdee, D. Stevenson, F. C. Warrander, K. Gilroy, C. Nixon, , O. J. Sansom

This study shows eIF4A1 is critical for supporting translational demands in Wnt-driven colorectal cancers, while eIF4A2 loss accelerates tumourigenesis, and eFT226 inhibits eIF4A1 function in these models.

bioRxiv · Nov 10, 2023 · PreprintCancer Biology

Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target

J. Vande Voorde, A. K. Najumudeen, R. T. Steven, C. J. Nikula, A. Dexter, L. B. Zeiger, E. A. Elia, A. Nassif, A. Gonzalez-Fernandez, T. Murta, M. Gillespie, C. A. Ford, T. R. M. Lannagan, N. Vlahov, R. A. Ridgway, , O. J. Sansom

This study uses metabolomics to stratify colorectal cancer tissues and identifies adenosylhomocysteinase as a potential therapeutic target.

bioRxiv · Mar 12, 2023Cancer Biology

Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K

J. R. Knight, N. Vlahov, D. M. Gay, R. A. Ridgway, L. Faller, C. Proud, G. R. Mallucci, T. von der Haar, C. M. Smales, A. E. Willis, O. J. Sansom

The paper shows that Rpl24Bst mutation suppresses colorectal cancer by enhancing eEF2 phosphorylation through eEF2K, reducing protein synthesis and tumorigenesis.

bioRxiv · May 5, 2021Cancer Biology

RASSF1C oncogene elicits amoeboid invasion, cancer stemness and invasive EVs via a novel SRC/Rho axis

M. L. Tognoli, N. Vlahov, S. Steenbeek, A. M. Grawenda, M. Eyres, D. Cano-Rodriguez, S. Scrace, C. Kartsonaki, A. von Kriegsheim, E. Willms, M. Wood, M. G. Rots, J. van Rheenen, E. O'Neill, D. Pankova

This study shows RASSF1C promotes amoeboid invasion, cancer stemness, and invasive extracellular vesicles through SRC/Rho axis activation in breast cancer.

bioRxiv · Jan 5, 2021Cancer Biology